Pfizer Inc. (NYSE:PFE) Shares Sold by Todd Asset Management LLC

Todd Asset Management LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 69.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,724 shares of the biopharmaceutical company’s stock after selling 17,268 shares during the quarter. Todd Asset Management LLC’s holdings in Pfizer were worth $222,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. SFE Investment Counsel lifted its stake in Pfizer by 5.9% during the 3rd quarter. SFE Investment Counsel now owns 127,269 shares of the biopharmaceutical company’s stock valued at $4,222,000 after acquiring an additional 7,065 shares during the period. Eclectic Associates Inc. ADV boosted its holdings in Pfizer by 3.2% in the third quarter. Eclectic Associates Inc. ADV now owns 25,322 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 797 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Pfizer by 0.3% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,794,489 shares of the biopharmaceutical company’s stock worth $59,515,000 after purchasing an additional 5,042 shares during the period. SevenBridge Financial Group LLC raised its stake in shares of Pfizer by 5.4% during the 3rd quarter. SevenBridge Financial Group LLC now owns 143,243 shares of the biopharmaceutical company’s stock valued at $4,751,000 after buying an additional 7,382 shares during the last quarter. Finally, Signet Financial Management LLC lifted its holdings in shares of Pfizer by 4.7% in the 3rd quarter. Signet Financial Management LLC now owns 39,861 shares of the biopharmaceutical company’s stock valued at $1,322,000 after buying an additional 1,773 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.4 %

NYSE PFE traded up $0.11 on Friday, reaching $27.81. 60,568,852 shares of the company were exchanged, compared to its average volume of 41,900,304. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37. The business’s fifty day moving average price is $26.88 and its 200 day moving average price is $28.21. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.23 EPS. Equities analysts expect that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Analyst Ratings Changes

Several brokerages recently weighed in on PFE. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $36.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.